Immunotherapy in locally advanced cervix cancer: A critical appraisal of the FDA indication based on ENGOT-CX11/GOG-3047/KEYNOTE-A18

Gynecol Oncol. 2024 Sep:188:81-82. doi: 10.1016/j.ygyno.2024.06.005. Epub 2024 Jun 26.
No abstract available

Publication types

  • Editorial

MeSH terms

  • Drug Approval
  • Female
  • Humans
  • Immune Checkpoint Inhibitors / therapeutic use
  • Immunotherapy / methods
  • United States
  • United States Food and Drug Administration*
  • Uterine Cervical Neoplasms* / immunology
  • Uterine Cervical Neoplasms* / pathology
  • Uterine Cervical Neoplasms* / therapy

Substances

  • Immune Checkpoint Inhibitors